



Response To Anti TNF Treatments According To Sex In Patients Followed For Spondyloarthritis (Spa)

F.E Bennani , H. Bara , R. Ait benaaddi , A.Mougui , I.El Bouchti
University hospital , rheumatology, Marrakech, Morocco

INTRODUCTION

Biotherapies are a class of drugs that have revolutionized the treatment of spondyloarthritis (AS). Over the years, numerous studies have been conducted to evaluate the effectiveness of biotherapies in the treatment of spondyloarthritis, and the results have been very encouraging. The objective of our study was to determine whether gender was a factor in a good response to anti-TNF alpha therapy in patients treated for SpA.

PATIENTS AND METHODS

A Retrospective study was conducted in the Rheumatology department, including patients followed for SpA under treatment with Anti TNF alpha.All patients met the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial SpA and were treated with anti-TNF for at least 12 months.. Data analysis was done by SPSS software version 22 and the significance value of p was 0.05. Therapeutic efficiency was assessed by BASDAI, a therapeutic response was defined by a BASDAI less than 4. The therapeutic response to anti-TNF after 3 and 6 months of evaluation was compared between two groups: group 1: female spondyloarthritis and group 2: male spondyloarthritis.

RÉSULTATS

In this study, 75 patients were included. The average age was 39.11 years with a male predominance (64%). Extra-articular manifestations were noted in 50.7% of patients. Axial involvement was noted in 89.3% of patients and enthesal involvement in 46.7%. The average age of onset of symptoms was 29.9 years and the average duration of evolution was 9.35 years. In terms of treatment, 25 patients (33.3%) were on Etanercept, 32 (42.6%) on Infliximab, 8 (10.6%) on Adalimumab and 10 patients(13.3%) on Golimumab. (Figure1). The response to anti-TNF alpha was compared between the female and male SPA groups, and the results are presented in the following table1 .




Figure 1: Distribution of biological treatments

	Women's SPA	Men's SPA	p-value
Number (%)	36	64	-
Age (years)	49.5	39.2	0.004
Mean age at start of anti-TNF treatment	45.63	36.44	0.021
Average duration of disease progression (years)	9.3	9.5	0.74
BASDAI initial mean	5.6	5.3	0.51
Average BASDAI at 3rd month	3.1	3.34	0.6
Average BASDAI at 6th month	2.6	3.25	0.11

Table 1: Comparison of results by gender

CONCLUSION

In our study, there was no statistically significant difference in response to anti-TNF alpha in patients with spondyloarthritis according to gender.